PE Anti-Galectin 8 / Gal-8 antibody [EPR4857]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(0 Publication)
Rabbit Recombinant Monoclonal Galectin 8/Gal-8 antibody - conjugated to PE.
View Alternative Names
Galectin-8, Gal-8, Po66 carbohydrate-binding protein, Prostate carcinoma tumor antigen 1, Po66-CBP, PCTA-1, LGALS8
Related conjugates and formulations (10)
-
660 APC
APC Anti-Galectin 8 / Gal-8 antibody [EPR4857]
-
HRP Anti-Galectin 8 / Gal-8 antibody [EPR4857]
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-Galectin 8 / Gal-8 antibody [EPR4857]
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-Galectin 8 / Gal-8 antibody [EPR4857]
-
617 Alexa Fluor® 594
Alexa Fluor® 594 Anti-Galectin 8 / Gal-8 antibody [EPR4857]
-
565 Alexa Fluor® 555
Alexa Fluor® 555 Anti-Galectin 8 / Gal-8 antibody [EPR4857]
-
603 Alexa Fluor® 568
Alexa Fluor® 568 Anti-Galectin 8 / Gal-8 antibody [EPR4857]
-
775 Alexa Fluor® 750
Alexa Fluor® 750 Anti-Galectin 8/Gal-8 antibody [EPR4857]
-
Anti-Galectin 8/Gal-8 antibody [EPR4857]
-
Anti-Galectin 8/Gal-8 antibody [EPR4857] - BSA and Azide free
Product details
This conjugated primary antibody is "made to order" and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link® conjugation technology, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Galectin-8 impacts numerous cellular functions through its involvement in immunomodulation and cell migration. Gal-8 promotes adhesion between cells and the extracellular matrix. It is not a part of a larger protein complex but interacts with multiple cell surface receptors guiding them toward or away from specific locations. Galectins including Galectin-8 influence immune cell responses by managing the apoptosis of T-cells and modifying cytokine production.
Pathways
Galectin-8 engages in signaling pathways related to cellular adhesion and immune system modulation. It participates in the integrin-mediated cell adhesion pathway and contributes to the receptor signaling pathway associated with cytokines. Within these pathways Galectin-8 interacts with other proteins such as integrins and T-cell receptors influencing their activation internalization and cell surface retention.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com